<DOC>
	<DOCNO>NCT02820454</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . AGuIX particle may increase effectiveness radiation therapy make tumor cell sensitive radiation . PURPOSE : This first-in-man Phase I trial study side effect best dose AGuIX inject together whole brain radiation therapy treat patient multiple brain metastasis . The effectiveness combination AGuIX radiation therapy also assess .</brief_summary>
	<brief_title>Radiosensitization Multiple Brain Metastases Using AGuIX Gadolinium Based Nanoparticles</brief_title>
	<detailed_description>The present study investigate safety , tolerability spectrum side effect AGuIX combination whole brain radiation therapy . As , study characterize dose limit toxicity ( DLT ) maximum tolerate dose ( MTD ) combination whole brain radiation therapy patient multiple brain metastasis . On day 1 , patient receive single intravenous injection AGuIX . An MRI scan perform 2 hour injection visualize distribution AGuIX brain metastasis surround healthy tissue , evaluate contrast enhancement brain metastasis . Then patient undergo whole brain radiation therapy , start 4 hour AGuIX injection , completion 2 week , 5 day week treatment ( 30Gy , 3Gy/fraction ) . During first 24h injection , several blood draw also perform order ass pharmacokinetic AGuIX . After completion study treatment , patient follow periodically . Patients enrol cohort treat sequentially rise dose level AGuIX combine whole brain radiation therapy . Three subject initially enter dose . If none three experience dose-limiting toxicity proceed next dose . If one three experience level toxicity , accrue 3 subject dose . If time two dose-limiting toxicity ( 3-6 subject ) give dose , drop low dose . Dose escalation continue MTD AGuIX whole brain radiation therapy establish . The MTD one dose DLT occur least 1 3 subject ( 2 6 patient ) .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Patients brain metastasis ineligible local treatment surgery stereotactic radiation At least 18 year old Secondary brain metastasis histologically confirm solid tumor Patient competent give inform consent ( ou Signed informed consent inform patient ) Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 3 No prior brain irradiation No renal insufficiency ( glomerular filtration rate &gt; 60 mL/min/1.73m² ) Normal liver function ( bilirubin &lt; 30 µmol/L ; Alkaline phosphatase &lt; 400 UI/L ; Aspartate aminotransferase ( AST ) &lt; 75 UI/L ; Alanine aminotransferase ( ALT ) &lt; 175 UI/L ) For male female patient , effective method contraception must use throughout study . Acceptable method contraception oral implantable contraceptive , intrauterine device , condom , spermicidal gel , surgical sterilization . Affiliated social security scheme assimilate Exclusion criterion : Meningeal carcinomatosis Progressive threaten extracranial disease Previous cranial irradiation ( whether whole partial brain radiation therapy , except stereotactic irradiation ) total body irradiation Known contraindication , sensitivity allergy gadolinium Patients unable undergo tolerate Magnetic Resonance Imaging Patients participate another clinical investigation time Protected person article L11215 L11218 , Code Public Health</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>AGuIX</keyword>
	<keyword>polysiloxane gadolinium-chelates base nanoparticles</keyword>
</DOC>